Results 51 to 60 of about 19,412 (203)

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

, 2023
BACKGROUND Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations.
Rukazenkov, Y, Cheng, Y, Yanagitani, N, Ahmed, S, Andrasina, I, Jänne, PA, Fan, Y, Ghiorghiu, D, Yang, JCH, Kim, SW, Valdiviezo, N, Yu, Y, Laktionov, K, Todd, A, Planchard, D, Sugawara, S, Maurel, JM, Geater, SL, Kobayashi, K, Lee, CK, Goldman, J   +20 more
core   +2 more sources

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer

Cell Death and Disease
Acquired resistance is inevitable in the treatment of non-small cell lung cancer (NSCLC) with osimertinib, and one of the primary mechanisms responsible for this resistance is the epithelial-mesenchymal transition (EMT).
Jing Zhou, Xinyue Wang, Zhaona Li, Fan Wang, Lianjing Cao, Xiuqiong Chen, Dingzhi Huang, Richeng Jiang   +7 more
doaj   +1 more source

The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment

British Journal of Clinical Pharmacology, EarlyView.
Background Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) have substantially improved outcomes in non‐small cell lung cancer (NSCLC); however, the development of treatment resistance remains a major clinical challenge. This study examines the association between concomitant prescriptions of H1‐antihistamines (H1AHs) and ...
Van Thuan Nguyen, Ngoc Hoang Le, Nhu Quynh Phan, Toan Trung Duong, Le Thi Anh Thu, Hsuan‐Chia Yang, Chih‐Wei Huang, Min‐Huei Hsu, Jason C. Hsu, Chien‐Tien Su, Phung‐Anh Nguyen   +10 more
wiley   +1 more source

Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study

International Journal of Cancer, EarlyView.
As third‐generation EGFR‐tyrosine kinase inhibitors, both aumolertinib and osimertinib demonstrate clinical efficacy for non‐small cell lung adenocarcinoma, especially in patients with brain metastases. Currently, head‐to‐head studies comparing these two agents in real‐world settings are scarce.
Jinxia Wang, Ping Qi, Jinhua Li, Na Wang, Caihong Fu, Lixin Liu, Shuping Li, Xiao Li, Xiaoming Hou, Hui Qiao   +9 more
wiley   +1 more source

Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC

Scientific Reports, 2022
Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer (NSCLC) who ...
Kei Kunimasa, Kazumi Nishino, Yoshiharu Sato, Masahide Mori, Shoichi Ihara, Hidekazu Suzuki, Izumi Nagatomo, Toru Kumagai, Toshitaka Morishima, Fumio Imamura   +9 more
doaj   +1 more source

Infographic – INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

, 2022
Infographic – MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib.
Karl Maria Schumacher (11850371), Xiuning Le (11850350), Svenja Adrian (11850365), Viola W Zhu (11850359), Egbert F Smit (9252899), Masahire Morise (11850356), Julien Mazieres (1837), Yi-Long Wu (154004), Figshare Future Science Group (6457551), Daniel Tan (840024), How Soon Hin (11850353), Kristina H Holmberg (11850362), Niki Karachaliou (458283), Jo Raskin (8677218), Ernest Nadal (709876), Sabine Brutlach (11850368), Christophe Dooms (2938749), Barbara Ellers-Lenz (11294394), Lye Mun Tho (8505159)   +18 more
core   +1 more source

Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives

JSFA reports, EarlyView.
Abstract Cancer is constantly rising mortality rates due to its late prognosis, poor management, and expensive treatment. Multi‐sectoral approaches for cancer management include hygienic practices, synthetic drug exploitation, radiation therapy, and diet modifications.
Muhammad Maaz, Muhammad Tauseef Sultan, Muhammad Israr, Waqas Ahmad Khan, Fahad Tanveer, Muzzamal Hussain, Muhammad Imran, Ahmed Mujtaba, Anjuman Gul Memon, Muhammad Atif, Entessar Al Jbawi   +10 more
wiley   +1 more source

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC [PDF]

, 2020
BACKGROUND: Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.
조병철
core   +2 more sources

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms

The Clinical Respiratory Journal
Background Osimertinib is approved as a standard treatment for non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation by FDA.
Xin Liao, Tingting He, Xiong Wan, Pian Liu, Jing Li, Yong He, Yubo Wang   +6 more
doaj   +1 more source